<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01493687</url>
  </required_header>
  <id_info>
    <org_study_id>RD.06.SPR.18170</org_study_id>
    <nct_id>NCT01493687</nct_id>
  </id_info>
  <brief_title>Phase 3 Papulopustular Rosacea Study</brief_title>
  <official_title>A Phase 3 Randomized, Double Blind, 12 Week Vehicle Controlled, Parallel Group Study Assessing the Efficacy and Safety of CD5024 1 % Cream Versus Vehicle Cream in Subjects With Papulopustular Rosacea, Followed by a 40 Week Investigator Blinded Extension Comparing the Long Term Safety of CD5024 1% Cream Versus Azelaic Acid 15 % Gel.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galderma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galderma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate that CD5024 1% cream is more effective than its
      vehicle when applied once daily, at bed time, during a 12 week period in subjects with
      Papulopustular Rosacea (PPR) and continues to be safe up to 12 months.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Success Rate</measure>
    <time_frame>Week 12</time_frame>
    <description>Percentage of subjects who achieve &quot;Clear&quot; (Score 0) or &quot;Almost Clear&quot; (Score 1) at Week 12 (ITT-LOCF) based on the Investigator Global Assessment (IGA) Score.
Evaluation of papulopustular rosacea will be performed by the investigator based on the following 5 point scale:
Clear = 0 (No inflammatory lesions present, no erythema); Almost Clear = 1 (Very few small papules/pustules, very mild erythema present); Mild = 2 (Few small papules/pustules, mild erythema); Moderate = 3 (Several small or large papules/pustules, moderate erythema); Severe = 4 (Numerous small and/or large papules/pustules, severe erythema)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute Change in Inflammatory Lesion Count</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Inflammatory lesion counts were conducted at each visit by the Investigator or study coordinator. Papules and pustules were counted separately on each of the five facial regions (forehead, chin, nose, right cheek, left cheek).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Inflammatory Lesion Count From Baseline to Week 12 (ITT-LOCF)</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Inflammatory lesion counts were conducted at each visit by the Investigator or study coordinator. Papules and pustules were counted separately on each of the five facial regions (forehead, chin, nose, right cheek, left cheek).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">683</enrollment>
  <condition>Papulopustular Rosacea (PPR)</condition>
  <arm_group>
    <arm_group_label>CD5024</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CD5024 1% Cream</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CD5024 Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>CD5024 Vehicle Cream</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CD5024</intervention_name>
    <description>CD5024 1% Cream, once daily</description>
    <arm_group_label>CD5024</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azelaic acid 15% Gel</intervention_name>
    <description>Topical Gel applied twice daily</description>
    <arm_group_label>CD5024 Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The subject has papulopustular rosacea with an Investigator Global Assessment (IGA)
             score rated 3 (moderate) or 4 (severe),

          2. The subject has at least 15 but not more than 70 inflammatory lesions (papules and
             pustules) on the face.

        Exclusion Criteria:

          1. The subject has particular forms of rosacea (rosacea conglobata, rosacea fulminans,
             isolated rhinophyma, isolated pustulosis of the chin) or other facial dermatoses that
             may be confounded with papulopustular rosacea, such as peri oral dermatitis, facial
             keratosis pilaris, seborrheic dermatitis, and acne,

          2. The subject has rosacea with more than two nodules on the face.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Graeber, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Galderma R&amp;D, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UAB Dermatology Clinical Research</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest AR Clinical Trials Center</name>
      <address>
        <city>Rogers</city>
        <state>Arkansas</state>
        <zip>72758</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Research Associates</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>30127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinical Trials</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Across America</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cherry Creek Research, Inc.</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Clinical &amp; Cosmetic Research</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Dermatology and Aesthetic Center</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Florida Dermatology Associates</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FXM Research Miramar</name>
      <address>
        <city>Miramar</city>
        <state>Florida</state>
        <zip>33027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedaPhase, Inc.</name>
      <address>
        <city>Newman</city>
        <state>Georgia</state>
        <zip>30263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laser &amp; Skin Surgery Center of Indiana</name>
      <address>
        <city>Carmel</city>
        <state>Indiana</state>
        <zip>46032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Indiana Clinical Trials Center</name>
      <address>
        <city>Plainfield</city>
        <state>Indiana</state>
        <zip>46168</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The South Bend Clinic, LLP</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46617</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Derm Research, PLLC</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lawrence Green, MD, LLC</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health Systems Department of Dermatology</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grekin Skin Institute</name>
      <address>
        <city>Warren</city>
        <state>Michigan</state>
        <zip>48088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Dermatology PC</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skin Specialists, PC</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anderson &amp; Collins Clinical Research,</name>
      <address>
        <city>Edison</city>
        <state>New Jersey</state>
        <zip>08817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Charlotte</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28277</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Research Associates</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Dermatology - Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Research Center of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haber Dermatology Clinical Research Center</name>
      <address>
        <city>South Euclid</city>
        <state>Ohio</state>
        <zip>44118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Sooner Research</name>
      <address>
        <city>Norman</city>
        <state>Oklahoma</state>
        <zip>73071</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baker Allergy, Asthma and Dermatology Research Center</name>
      <address>
        <city>Lake Oswego</city>
        <state>Oregon</state>
        <zip>97035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Charleston</name>
      <address>
        <city>Mt. Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palmetto Clinical Trial Services, LLC</name>
      <address>
        <city>Simpsonville</city>
        <state>South Carolina</state>
        <zip>29681</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TriCities Skin and Cancer</name>
      <address>
        <city>Johnson City</city>
        <state>Tennessee</state>
        <zip>37604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Associates of Kingsport, PC</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DermResearch, Inc.</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Modern Research Associates</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Clinical Studies</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Progressive Clinical Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Research Center, Inc.</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Education &amp; Research Foundation, Inc.</name>
      <address>
        <city>Lynchburg</city>
        <state>Virginia</state>
        <zip>24501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PLLC dba Dermatology Associates</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Polyclinic</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stratica Medical Inc</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T5K 1X3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Derm Research@888 Inc.</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 3Y1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermadvances Research</name>
      <address>
        <city>Winnepeg</city>
        <state>Manitoba</state>
        <zip>R3C 1R4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nexus Clinical Research</name>
      <address>
        <city>St John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1A 5E8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern Canada Cutaneous Research Associates</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skin Centre for Dermatology</name>
      <address>
        <city>Peterborough</city>
        <state>Ontario</state>
        <zip>K9J 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto Research Centre, Inc.</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M3H 5Y8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Windsor Clinical Research, Inc.</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8W 5L7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innovaderm Research. Inc</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2K 4L5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siena Medical</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3Z 2S6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 14, 2011</study_first_submitted>
  <study_first_submitted_qc>December 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2011</study_first_posted>
  <results_first_submitted>January 8, 2015</results_first_submitted>
  <results_first_submitted_qc>January 15, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 16, 2015</results_first_posted>
  <disposition_first_submitted>January 27, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>January 27, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 28, 2014</disposition_first_posted>
  <last_update_submitted>January 15, 2015</last_update_submitted>
  <last_update_submitted_qc>January 15, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosacea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azelaic acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>CD5024 1% Cream</title>
          <description>Part A &amp; B: CD5024 1% Cream, once daily application</description>
        </group>
        <group group_id="P2">
          <title>CD5024 Vehicle Cream/Azelaic Acid 15% Gel</title>
          <description>Part A: CD5024 Vehicle Cream, once daily application
Part B: Azelaic acid 15% Gel, twice daily application</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Part A Vehicle Control (12 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="451"/>
                <participants group_id="P2" count="232"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="414"/>
                <participants group_id="P2" count="210"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other (noted on CRF)</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part B Long Term Active Control 40 Weeks</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="412">414 completed Part A. Then 2 discontinued (lack of efficacy, subject request) prior to Part B.</participants>
                <participants group_id="P2" count="210"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="351"/>
                <participants group_id="P2" count="175"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other (noted on eCRF)</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part C Safety Follow up (4 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="350">351 completed Part B. Then 1 discontinued (subject request) prior to Part C.</participants>
                <participants group_id="P2" count="175"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="350"/>
                <participants group_id="P2" count="174"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>ITT population</population>
      <group_list>
        <group group_id="B1">
          <title>CD5024 1% Cream</title>
          <description>Part A: CD5024 1% Cream, once daily application for 12 weeks Part B: CD5024 1% Cream, once daily application for 40 weeks</description>
        </group>
        <group group_id="B2">
          <title>CD5024 Vehicle Cream/Azelaic Acid 15% Gel</title>
          <description>Part A: CD5024 Vehicle Cream, once daily application for 12 weeks
Part B: Azelaic acid 15% Gel, twice daily application for 40 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="451"/>
            <count group_id="B2" value="232"/>
            <count group_id="B3" value="683"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.9" spread="12.15"/>
                    <measurement group_id="B2" value="51.6" spread="11.92"/>
                    <measurement group_id="B3" value="50.4" spread="12.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="314"/>
                    <measurement group_id="B2" value="152"/>
                    <measurement group_id="B3" value="466"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="137"/>
                    <measurement group_id="B2" value="80"/>
                    <measurement group_id="B3" value="217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="396"/>
                    <measurement group_id="B2" value="209"/>
                    <measurement group_id="B3" value="605"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="437"/>
                    <measurement group_id="B2" value="220"/>
                    <measurement group_id="B3" value="657"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Skin Photo Type</title>
          <description>DEFINITION OF SKIN PHOTOTYPE (T.B. Fitzpatrick):
I: Always burns easily ; never tans II: Always burns easily ; tans minimally and with difficulty III: Burns minimally ; tans gradually and uniformly (light Brown) IV: Burns minimally ; always tans well (moderate brown) V: Rarely burns ; tans profusely (dark brown)) VI:Never burns ; deeply pigmented (black), tans profusely</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="185"/>
                    <measurement group_id="B2" value="90"/>
                    <measurement group_id="B3" value="275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="167"/>
                    <measurement group_id="B2" value="86"/>
                    <measurement group_id="B3" value="253"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Success Rate</title>
        <description>Percentage of subjects who achieve &quot;Clear&quot; (Score 0) or &quot;Almost Clear&quot; (Score 1) at Week 12 (ITT-LOCF) based on the Investigator Global Assessment (IGA) Score.
Evaluation of papulopustular rosacea will be performed by the investigator based on the following 5 point scale:
Clear = 0 (No inflammatory lesions present, no erythema); Almost Clear = 1 (Very few small papules/pustules, very mild erythema present); Mild = 2 (Few small papules/pustules, mild erythema); Moderate = 3 (Several small or large papules/pustules, moderate erythema); Severe = 4 (Numerous small and/or large papules/pustules, severe erythema)</description>
        <time_frame>Week 12</time_frame>
        <population>LOCF, ITT</population>
        <group_list>
          <group group_id="O1">
            <title>CD5024 1% Cream</title>
            <description>CD5024: CD5024 1% Cream, once daily application for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>CD5024 Vehicle Cream</title>
            <description>CD5024 Vehicle Cream, once daily application for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Success Rate</title>
          <description>Percentage of subjects who achieve &quot;Clear&quot; (Score 0) or &quot;Almost Clear&quot; (Score 1) at Week 12 (ITT-LOCF) based on the Investigator Global Assessment (IGA) Score.
Evaluation of papulopustular rosacea will be performed by the investigator based on the following 5 point scale:
Clear = 0 (No inflammatory lesions present, no erythema); Almost Clear = 1 (Very few small papules/pustules, very mild erythema present); Mild = 2 (Few small papules/pustules, mild erythema); Moderate = 3 (Several small or large papules/pustules, moderate erythema); Severe = 4 (Numerous small and/or large papules/pustules, severe erythema)</description>
          <population>LOCF, ITT</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="451"/>
                <count group_id="O2" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.4"/>
                    <measurement group_id="O2" value="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Absolute Change in Inflammatory Lesion Count</title>
        <description>Inflammatory lesion counts were conducted at each visit by the Investigator or study coordinator. Papules and pustules were counted separately on each of the five facial regions (forehead, chin, nose, right cheek, left cheek).</description>
        <time_frame>Baseline to Week 12</time_frame>
        <population>LOCF, ITT</population>
        <group_list>
          <group group_id="O1">
            <title>CD5024 1% Cream</title>
            <description>CD5024: CD5024 1% Cream, once daily application for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>CD5024 Vehicle Cream</title>
            <description>CD5024 Vehicle Cream, once daily application for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change in Inflammatory Lesion Count</title>
          <description>Inflammatory lesion counts were conducted at each visit by the Investigator or study coordinator. Papules and pustules were counted separately on each of the five facial regions (forehead, chin, nose, right cheek, left cheek).</description>
          <population>LOCF, ITT</population>
          <units>Lesion count change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="451"/>
                <count group_id="O2" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.5" spread="15.95"/>
                    <measurement group_id="O2" value="-12.0" spread="13.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-8.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.12</ci_lower_limit>
            <ci_upper_limit>-6.13</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Inflammatory Lesion Count From Baseline to Week 12 (ITT-LOCF)</title>
        <description>Inflammatory lesion counts were conducted at each visit by the Investigator or study coordinator. Papules and pustules were counted separately on each of the five facial regions (forehead, chin, nose, right cheek, left cheek).</description>
        <time_frame>Baseline to Week 12</time_frame>
        <population>LOCF, ITT</population>
        <group_list>
          <group group_id="O1">
            <title>CD5024 1% Cream</title>
            <description>CD5024: CD5024 1% Cream, once daily application for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>CD5024 Vehicle Cream</title>
            <description>CD5024 Vehicle Cream, once daily application for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Inflammatory Lesion Count From Baseline to Week 12 (ITT-LOCF)</title>
          <description>Inflammatory lesion counts were conducted at each visit by the Investigator or study coordinator. Papules and pustules were counted separately on each of the five facial regions (forehead, chin, nose, right cheek, left cheek).</description>
          <population>LOCF, ITT</population>
          <units>Percentage of change in lesion counts</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="451"/>
                <count group_id="O2" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-64.9" spread="39.91"/>
                    <measurement group_id="O2" value="-41.6" spread="38.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Time of signed informed consent to study end (~ 58 wks). Treatment emergent adverse events - occurred on date of 1st use of medication or after, except those reported from Day 1 lab data as blood sample was to be drawn before the time of 1st dose.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>CD5024 1% Cream - Part A</title>
          <description>Part A: CD5024 1% Cream, once daily application for 12 weeks</description>
        </group>
        <group group_id="E2">
          <title>CD5024 Vehicle Cream - Part A</title>
          <description>Part A: CD5024 Vehicle Cream, once daily application for 12 weeks</description>
        </group>
        <group group_id="E3">
          <title>CD5024 1% Cream - Part B</title>
          <description>Part B CD5024 1% Cream, once daily application for 40 weeks</description>
        </group>
        <group group_id="E4">
          <title>Azelaic Acid 15% Gel - Part B</title>
          <description>Part B: Subjects in the CD5024 Vehicle Cream arm applied Azelaic Acid 15% Gel twice daily for 40 weeks</description>
        </group>
        <group group_id="E5">
          <title>CD5024 1% Cream - Part C</title>
          <description>Part C: 4 week safety follow up. No drug applications</description>
        </group>
        <group group_id="E6">
          <title>CD5024 Vehicle Cream/Azelaic Acid 15% Gel - Part C</title>
          <description>Part C: 4 week safety follow up. No drug applications</description>
        </group>
        <group group_id="E7">
          <title>CD5024 1% Cream - Overall</title>
          <description>Overall number of subjects with adverse events for the entire duration of study</description>
        </group>
        <group group_id="E8">
          <title>CD5024 Vehicle Cream/Azelaic Acid 15% Gel - Overall</title>
          <description>Overall number of subjects with adverse events for the entire duration of study</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="412"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="210"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E7" subjects_affected="10" subjects_at_risk="452"/>
                <counts group_id="E8" subjects_affected="9" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="210"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oesophageal ulcer perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="210"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Intra-uterine death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="210"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Femoral arterial stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Haemorrhagic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="93" subjects_at_risk="412"/>
                <counts group_id="E4" subjects_affected="47" subjects_at_risk="210"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="350"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E7" subjects_affected="110" subjects_at_risk="452"/>
                <counts group_id="E8" subjects_affected="52" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="54" subjects_at_risk="412"/>
                <counts group_id="E4" subjects_affected="31" subjects_at_risk="210"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E7" subjects_affected="63" subjects_at_risk="452"/>
                <counts group_id="E8" subjects_affected="34" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="412"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="210"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="350"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E7" subjects_affected="37" subjects_at_risk="452"/>
                <counts group_id="E8" subjects_affected="16" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="412"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="210"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E7" subjects_affected="26" subjects_at_risk="452"/>
                <counts group_id="E8" subjects_affected="10" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>At least sixty (60) days prior to submission for publication, presentation or use, the Institution and the Investigator shall submit in writing to the Contract Research Organization and Sponsor for review and comment any proposed oral or written publication, which period may be extended for an additional thirty (30) days if requested in writing by Contract Research Organization and Sponsor.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Science Director</name_or_title>
      <organization>Galderma R&amp;D, LLC</organization>
      <phone>609-409-7701</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

